Skip to main content
David Kelley, MD, Endocrinology, Pittsburgh, PA

DavidEKelleyMD

Endocrinology Pittsburgh, PA

Diabetes, Lipid Metabolism

Vice President, Franchise Integrator for Diabetes & Obesity

Are you Dr. Kelley?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 49 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. David Kelley, MD is an endocrinologist in Pittsburgh, Pennsylvania. He is currently licensed to practice medicine in New Jersey. He is a Vice President at Franchise Integrator for Diabetes & Obesity.

Education & Training

  • Mayo Clinic College of Medicine and Science (Rochester)
    Mayo Clinic College of Medicine and Science (Rochester)Fellowship, Endocrinology, Diabetes, and Metabolism, 1985 - 1987
  • University of Maryland
    University of MarylandResidency, Internal Medicine, 1979 - 1981
  • Oregon Health & Science University
    Oregon Health & Science UniversityInternship, Internal Medicine, 1978 - 1979
  • University of Maryland School of Medicine
    University of Maryland School of MedicineClass of 1978

Certifications & Licensure

  • NJ State Medical License
    NJ State Medical License 2008 - 2019
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Potential Diabetes Target Makes Subtle Changes with Big Impact on Metabolic Health
    Potential Diabetes Target Makes Subtle Changes with Big Impact on Metabolic HealthJuly 5th, 2019
  • Tiny Change Has Big Effects, Reverses Prediabetes in Mice
    Tiny Change Has Big Effects, Reverses Prediabetes in MiceJuly 4th, 2019
  • Subtle Chemical Shift Reverses Prediabetes in Merck-Partnered Mouse Trial
    Subtle Chemical Shift Reverses Prediabetes in Merck-Partnered Mouse TrialJuly 2nd, 2019
  • Join now to see all

Grant Support

  • Mitochondrial Impairment In Muscle Insulin ResistanceNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2006
  • Obesity/Nutrition Research CenterNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2006
  • PET Imaging Of Regional Variation In Insulin Sensitivity Of Fatty Tissues HumansNational Center For Research Resources2005
  • Multi-Tracer PET Quantitation Of Insulin Action In MuscleNational Center For Research Resources2005
  • Multi-Tracer PET Quant Skeletal Muscle Insulin Resist Type 2 Diabetes MellitusNational Center For Research Resources2005
  • Mitochondrial Impairment In Muscle Insulin ResistanceNational Center For Research Resources2005
  • Look Ahead: Ancillary Study: MRI Derived Organ Tissue Mass Weight LossNational Center For Research Resources2005
  • Look Ahead Ancillary Study: Fat Cell Size, Muscle Lipid InfiltrationNational Center For Research Resources2005
  • Mitochondrial Impairment In Muscle Insulin ResistanceNational Center For Research Resources2004–2005
  • Look Ahead Study: Action For Health In DiabetesNational Center For Research Resources2004–2005
  • Look Ahead Ancillary Study: MRI Derived Organ And Tissue Mass Changes WithNational Center For Research Resources2004–2005
  • Study Of Health Outcomes Of Weight-Loss (SHOW)National Institute Of Diabetes And Digestive And Kidney Diseases2003–2005
  • PET Quant Skeletal Muscle Insulin Resist NIDDMNational Center For Research Resources2004
  • Multi-Tracer PET Quantitation Of Insulin In MuscleNational Center For Research Resources2004
  • Look Ahead: MRI Derived Organ/Tissue Weight LossNational Center For Research Resources2004
  • Look Ahead: Fat Cell Size, Muscle Lipid InfiltrationNational Center For Research Resources2004
  • Contrast Enhanced US Capillary Recruit MuscleNational Center For Research Resources2004
  • Multi-Tracer PET Quantitation Of Insulin ActionNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2004
  • Skeletal Muscle Metabolism Of Fatty AcidsNational Institute Of Diabetes And Digestive And Kidney Diseases2000–2004
  • Glucagon Receptor Antagonist BAY 27 9955 In NIDDMNational Center For Research Resources2000–2002
  • Clinical Center For Look Ahead: Health In DiabetesNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2002
  • Troglitazone, Metformin, &Sulfonylurea In Insulin Stimulated GlucoseNational Center For Research Resources1999–2002
  • SDZ Djn608 &Glyburideon In Basal &Postprandial Hepatic GlucoseNational Center For Research Resources1999–2002
  • Effects Of Obesity On Muscle FFA UtilizationNational Center For Research Resources1999–2002
  • Lipid Metabolism In Pregnancy And With PreeclampsiaNational Center For Research Resources1998–2002
  • Examination Of Skeletal Muscle Fat Content By Mri--Efects Of Obesity And NIDDMNational Center For Research Resources1998–2002
  • Core--Clinical Assessment FacilityNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2002
  • Effects Of NIDDM On Glucose Transport In Skeletal MuscleNational Center For Research Resources1996–2002
  • Obesity Effects On Muscle FFA UtilizationNational Institute Of Diabetes And Digestive And Kidney Diseases1998–2001
  • Clinafloxacin Effects On Sulfonylurea Control Of Glucose In NIDDMNational Center For Research Resources1998–2000
  • Troglitazone, Metformin &Sulfonylurea And Insulin Stimulated GlucoseNational Center For Research Resources1999
  • Effects Of Obesity On Muscle Free Fatty Acid UtilizationNational Center For Research Resources1999
  • FFA Metabolism By Skeletal Muscle In Niddm--Regulation By Short Term CaloriesNational Center For Research Resources1998–1999
  • Single Dose Study In Healthy Volunteers To Determine The Effect Of ClinafloxacinNational Center For Research Resources1997–1999
  • Effects Of Visceral Obesity On Muscle FFA MetabolismNational Center For Research Resources1996–1999
  • Six-Month Double-Blind Placebo-Controlled Study Of Troglitazone In NIDDMNational Center For Research Resources1996–1997
  • Visceral Obesity Effect On Muscle FFA UtilizationNational Institute Of Diabetes And Digestive And Kidney Diseases1995–1997
  • Skeletal Muscle Free Fatty Acid Uptake And Oxidation In ObesityNational Institute Of Diabetes And Digestive And Kidney Diseases1996
  • Skeletal Muscle FFA Oxidation During Exercise In NIDDMNational Center For Research Resources1996
  • Placebo-Controlled Safety And Efficacy Study Of Pimagedine In Type II DiabetesNational Center For Research Resources1996
  • In Vivo Assessment Of Skeletal Muscle Glucose Transport In NIDDMNational Center For Research Resources1996